Related Experiment Videos
Three novel single nucleotide polymorphisms in UGT1A10.
Mayumi Saeki1, Shogo Ozawa, Yoshiro Saito
1Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
Drug Metabolism and Pharmacokinetics
|December 25, 2004
Summary
Three novel single nucleotide polymorphisms (SNPs) were identified in the UGT1A10 gene of Japanese cancer patients treated with irinotecan. Two SNPs resulted in amino acid changes, potentially impacting drug metabolism and patient response.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Oncology
Background:
- The UDP-glucuronosyltransferase (UGT) 1A10 gene plays a role in drug metabolism.
- Irinotecan (CPT-11) is an anti-tumor drug used in cancer treatment.
- Genetic variations can influence drug efficacy and toxicity.
Purpose of the Study:
- To identify novel single nucleotide polymorphisms (SNPs) in the UGT1A10 gene.
- To investigate the frequency and impact of these SNPs in Japanese cancer patients receiving irinotecan.
Main Methods:
- Genomic DNA was isolated from 24 Japanese cancer patients treated with irinotecan.
- The UGT1A10 gene was analyzed for single nucleotide polymorphisms (SNPs).
- Detected SNPs were characterized for their location and potential effect on amino acid sequence.
Main Results:
- Three novel SNPs (MPJ6_U1A003, MPJ6_U1A004, MPJ6_U1A030) were identified in exon 1 of the UGT1A10 gene.
- All identified SNPs had a frequency of 0.021.
- MPJ6_U1A003 and MPJ6_U1A030 resulted in amino acid substitutions (T202I and M59I, respectively).
- MPJ6_U1A004 led to a synonymous amino acid change (A231A).
Conclusions:
- Novel SNPs in the UGT1A10 gene were discovered in Japanese cancer patients.
- Some of these SNPs cause amino acid alterations, suggesting potential implications for irinotecan metabolism.
- Further research is warranted to determine the clinical significance of these UGT1A10 gene variations in cancer therapy.